| Title: |
Pharmacogenetics of Mycophenolic Acid in Patients of African Descent: Underrepresentation of African Data. |
| Authors: |
Mouton, Migael; Davidson, Bianca; Taylor, Jessica; Blockman, Marc; Jones, Erika; Freercks, Robert; Mnika, Khuthala; Dandara, Collet |
| Source: |
CTS: Clinical & Translational Science; May2026, Vol. 19 Issue 5, p1-22, 22p |
| Abstract: |
Mycophenolic acid (MPA) is a potent antiproliferative immunosuppressive agent used to prevent organ transplant rejection and to treat various immune‐mediated diseases. MPA is the active metabolite formed from the biotransformation of the prodrugs mycophenolate mofetil (MMF) or enteric‐coated mycophenolate sodium (EC‐MPS). MPA exerts its therapeutic effects by inhibiting guanosine nucleotide synthesis in lymphocytes. Through this inhibition, cell and humoral immunity is suppressed, resulting in a reduction of cytotoxicity and inflammation. Systemic exposure to MPA is influenced by a complex pharmacokinetic pathway, which involves various drug‐metabolizing enzymes (DMEs) and transporters. Substantial interindividual variability exists in MPA exposure, efficacy, and adverse effects. Genetic polymorphisms in the genes encoding DMEs and transporters have been reported to influence this observed variability; however, evidence remains inconsistent and is largely derived from non‐African populations. African populations exhibit high levels of genetic diversity, and their underrepresentation in pharmacogenetic studies may hinder the identification of important variants influencing MPA disposition and clinical outcomes. This review evaluates the genes that have been reported to affect MPA exposure as well as highlights conflicting results on the role of these pharmacogenetic variants in different populations. The review highlights the lack of data on African populations and provides justification for their inclusion in the study of MPA pharmacogenetics. Study Highlights: What is the current knowledge on the topic?: Current knowledge shows that genetic variants in UGT enzymes, drug transporters, and IMPDH isoforms influence MPA exposure, toxicity, and treatment response. Most findings come from European and Asian cohorts, with African populations largely underrepresented despite a high disease burden. What question did this study address?: Does pharmacogenetics play a role in MMF/MPA exposure and treatment outcomes in patients of African populations? What does this study add to our knowledge?: This review highlights conflicting results in previous research, that there are gaps in ethnic‐specific data, and that there is a lack of inclusion of participants of African descent in MPA related pharmacogenetic research. How might this change clinical pharmacology or translational science?: The lack of African‐specific pharmacogenetic research on MPA exposure and treatment outcomes limits the accuracy of European‐based dosing strategies in African populations, thereby underscoring the need for population‐specific pharmacogenetic research to guide safe and effective MMF use. [ABSTRACT FROM AUTHOR] |
| : |
Copyright of CTS: Clinical & Translational Science is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |